01276.HK
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 50.70
+0.10%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +14.4%
- EBITDA
- +26.0%
- EPS
- +12.6%
Three-year CAGR
- Revenue
- +13.2%
- EBITDA
- +27.0%
- EBIT
- +28.8%
- Net income
- +24.5%
- EPS
- +24.1%
- Free cash flow
- +16.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026